Comparison 1. Antihypertensive vs. Control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total Serious Adverse Events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 All‐cause mortality	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Non‐fatal cardiovascular events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Acute Myocardial Infarction	1	48	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.31, 1.72]
4.1 ACE‐inhibitors vs. placebo	1	48	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.31, 1.72]
5 Respiratory insufficiency requiring mechanical ventilation	1	46	Risk Ratio (M‐H, Fixed, 95% CI)	0.4 [0.09, 1.86]
5.1 ACE‐I vs placebo	1	46	Risk Ratio (M‐H, Fixed, 95% CI)	0.4 [0.09, 1.86]
6 Withdrawals due to adverse events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Mean change in systolic blood pressure during treatment	1	118	Mean Difference (IV, Fixed, 95% CI)	‐13.14 [‐19.48, ‐6.80]
7.1 CCB vs. placebo	1	23	Mean Difference (IV, Fixed, 95% CI)	‐19.46 [‐31.17, ‐7.75]
7.2 ACE‐I vs. placebo	1	47	Mean Difference (IV, Fixed, 95% CI)	‐15.36 [‐26.53, ‐4.19]
7.3 A1A vs. placebo	1	48	Mean Difference (IV, Fixed, 95% CI)	‐6.46 [‐16.69, 3.77]
8 Mean change in diastolic blood pressure during treatment	1	92	Mean Difference (IV, Fixed, 95% CI)	‐8.03 [‐12.61, ‐3.45]
8.1 CCB vs. Placebo	1	23	Mean Difference (IV, Fixed, 95% CI)	‐10.36 [‐18.39, ‐2.33]
8.2 ACE‐I vs. placebo	1	47	Mean Difference (IV, Fixed, 95% CI)	‐6.94 [‐14.65, 0.77]
8.3 A1A vs. placebo	1	22	Mean Difference (IV, Fixed, 95% CI)	‐6.86 [‐14.93, 1.21]
9 Mean change in heart rate during treatment	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]